Thomas Durand-Reville

Head of US Medicinal Chemistry and Biophysical Sciences
Thomas Durand-Reville

Thomas heads the US Medicinal Chemistry and Biophysical Sciences team at Dewpoint, where he is leading drug discovery programs across multiple disease areas. He brings more than 20 years of industry and biotech experience.

Thomas received his Ph.D. in Chemistry from the Université Pierre et Marie Curie in Paris. After postdoctoral research at the University of Cambridge, Thomas started his medicinal chemistry career at Biogen and Wyeth where he led several small teams in oncology and inflammation and optimized small molecules from early hits to development candidates. One of these projects led to the discovery of the pan-Raf kinase inhibitor Tovorafenib (DAY101, Phase 3).

Later, in the AstraZeneca Infection group, he was responsible for the medicinal chemistry strategy on many antibacterial programs from early stage hit identification through IND-enabling studies. These efforts culminated in the discovery of the beta-lactamase inhibitor durlobactam (recently approved as Xacduro®).

He then joined Entasis Therapeutics (a spin-off from the AstraZeneca Infectious Disease department) as Head of Chemistry, where his group delivered a portfolio of new precision antibiotics against multidrug-resistant Gram-negative pathogens. Additionally, Thomas contributed to the inception and implementation of an innovative discovery platform focusing on bacterial permeation.

His direct scientific contributions have resulted in more than 40 patents and peer-reviewed publications. In his spare time, Thomas enjoys golfing and skiing with his wife and 2 children and is an avid wine enthusiast.

Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science